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ABSTRACT 
BACKGROUND:  Dihydropyridine calcium antagonists are largely employed for 
the treatment of hypertension, coronary heart disease, and heart failure. 
OBJECTIVW: The aim of our study was to compare the antihypertensive effect of 
the dihydropyridine calcium antagonists barnidipine and amlodipine. 
METHODS: This was a 24-week, randomized, open-label, pilot study. Consecutive 
treatment-naive patients with grade I or II essential hypertension (office sitting systolic 
blood pressure [BP] of 140-179 mm Hg and diastolic BP of 90-109 mm Hg) were 
enrolled. The primary end points were the effect of treatment with either barnidipine 
10 mg or amlodipine 5mg once daily on office and ambulatory BP, left ventricular mass 
index (LVMI), and markers of cardiac damage, serum procollagen type I C-terminal 
propeptide, and plasma mino-terminal pro-B-type natriuretic peptide concentrations. 
Patients were assessed at enrollment, and 12 and 24 weeks. During each visit, the preva- 
lence of adverse vents (AEs) was also monitored using spontaneous reporting, patient 
interview, and physical examination, the relationship to study drug being determined 
by the investigators. Compliance with treatment was assessed at each study visit by 
counting returned tablets. 
RESULTS: Thirty eligible patients (20 men, 10 women; mean [SD] age, 47 [12] years) 
were included in the study; all patients completed the 24 weeks of study treatment. 
Twelve weeks after randomization, 6 patients in the amlodipine group had their dose 
doubled to 10 mg due to inadequate BP control. Mean BP reductions at study end 
were not significantly different between the barnidipine and amlodipine groups (office 
BP, -10.3/-9.4 vs -16.6/-9.1 mm Hg; ambulatory BP, 9.4/6.4 vs 8.1/5.1 mm Hg). 
Reductions in LVMI and markers of cardiac damage were not significantly different 
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between the 2 groups. Significantly more patients in the amlodipine group reported 
drug-related AEs compared with those in the barnidipine group (9 [60%] vs 2 [13%]; 
P < 0.05). 
CONCLUSION:  In this small sample of treatment-naive hypertensive patients, the 
antihypertensive effect of barnidipine 10 mg once daily was not significantly differ- 
ent from that of amlodipine 5 to 10 mg once daily. (Curr Ther Res Clin Exp. 2008;69: 
192-206) © 2008 Excerpta Medica Inc. 
KEY WORDS: essential hypertension, ambulatory bloodpressure monitoring, 
barnidipine, amlodipine, left ventricular mass index, smoothness index. 
INTRODUCTION 
Due to their antihypertensive efficacy, dihydropyridine calcium antagonists are recom- 
mended by international guidelines as first-choice drugs for the treatment of hyperten- 
sion, coronary heart disease, and heart failure. 1-3 However, treatment with many of 
these drugs is associated with adverse vents (AEs), 4 which may reduce adherence to 
treatment and result in switching to other drug classes. 3 
Barnidipine is a long-acting dihydropyridine calcium antagonist 6,7 that has been 
evaluated in short- and long-term double-blind, randomized studies, and open-label 
studies of hypertensive patients of all ages. 8-11 In these studies, barnidipine was 
as effective in reducing blood pressure (BP) as monotherapy with other calcium 
antagonists (felodipine, amlodipine, and nitrendipine), 12-14 ~3-blockers (atenolol), 15 
angiotensin-converting enzyme (ACE) inhibitors (enalapril), 15 and diuretics (hydro- 
chlorothiazide). 16 Barnidipine was also reported to be effective and well tolerated in 
combination treatment with ~3-blockers or ACE inhibitors 1°,11,15 and throughout an 
entire 24-hour period in studies using ambulatory BP monitoring. 17,18 The safety pro- 
file of barnidipine appears better than that observed with other calcium antagonists, 
being <3%. 7 
In the present study, we compared the antihypertensive effect of treatment with 
barnidipine or amlodipine administered once daily. This study is unique in that the 
study participants were treatment-naive patients with primary hypertension. In addi- 
tion, we used ambulatory BP monitoring and measured left ventricular mass index 
(LVMI) and markers of cardiac fibrosis and function as our primary end points. 
PAT IENTS AND METHODS 
This single-center, andomized, open-label, parallel-group, ilot study was conducted at 
the Centro Interuniversitario di Fisiologia Clinica e Ipertensione, IRCCS Policlinico, 
Universit?~ di Milano, Milano, Italy. Written informed consent was obtained from all 
patients prior to their inclusion in the study. The study was approved by the indepen- 
dent institutional review board of the study center. 
STUDY POPULAT ION 
The study included consecutive eligible adult (aged _>18 years) outpatients of either 
sex with grade I or II essential hypertension (office sitting systolic BP [SBP] of 140- 
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179 mm Hg and/or office sitting diastolic BP [DBP] of 90-109 mm Hg). 3 All patients 
were naive to antihypertensive drug treatment and were enrolled between May 2005 
and April 2006. 
Patients were excluded if they met any of the following criteria: (1) malignant or 
secondary hypertension; (2) clinically significant heart disease (ie, cardiac valvular 
disease, major arrhythmias, heart failure, unstable angina, myocardial infarction) 
or cerebrovascular disease; (3) serious concomitant diseases (eg, renal insufficiency, 
malignancy, hepatic disorders, psychiatric disease, diabetes); (4) history of alcohol or 
drug abuse; (5) obesity (body mass index >30 kg/m2); or (6) known hypersensitivity 
to dihydropyridine calcium antagonists. Pregnant or breastfeeding women or women 
of childbearing potential who were not practicing an effective method of birth control 
were also excluded. 
STUDY DES IGN 
Patients were administered barnidipine 10 mg or amlodipine 5 mg once daily in 
the morning for 24 weeks. The starting doses were those recommended by regulatory 
authorities and producers 6,v and in guidelines 3. After the initial 12 weeks of treatment, 
barnidipine or amlodipine doses were doubled in patients with inadequate control 
(office SBP >140 mm Hg or office DBP >90 mm Hg). 
Randomization was accomplished through a computer-generated gri . The patient 
randomization numbers were allocated sequentially in the order in which the patients 
entered the study. The randomization code and treatment assigned were placed in a 
sealed envelope to be opened at the time of a patient's assignment to active treatment. 
Given the open-label design of the study, treatment identity was known to both the 
physician and the patient. 
At the screening visit, medical history was recorded and a physical examination and 
12-lead echocardiogram were performed. Physical examination was repeated after 12 and 
24 weeks of treatment. Office BP was measured at study initiation and after 12 and 
24 weeks of treatment. Twenty-four-hour ambulatory BP monitoring was performed 
at the initial and final visits. At study initiation and at the end of treatment, M-mode 
echocardiography was also performed and LVMI was computed. Blood samples were 
drawn at the initial and final visits to assess erum concentrations of procollagen type 
I C-terminal propeptide (PICP), a marker of collagen turnover used to quantify myo- 
cardial fibrosis, and plasma concentrations of amino-terminal pro-B-type natriuretic 
peptide (NT-proBNP), a biomarker of left ventricular dysfunction. 
During each visit, the prevalence of AEs was also monitored using spontaneous 
reporting, patient interview, and physical examination. Compliance with treatment was 
assessed at each study visit by counting returned tablets. 
BLOOD PRESSURE AND HEART RATE MEASUREMENT 
Patients' BP was measured in the clinic using a standard sphygmomanometer 
24 hours after drug administration. The mean of 3 measurements taken at 2-minute 
intervals after 5 minutes of rest in the sitting position was used as the office BP refer- 
ence value. SBP and DBP values were taken at the first and fifth Korotkoff sounds, 
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respectively. Heart rate (HR) was measured by palpating the radial artery pulse. Two 
physicians measured both BP and HR, with the same physician always examining the 
same patient. 
Ambulatory BP monitoring was performed noninvasively over 24 hours using an 
oscillometric validated evice (Spacelabs 90207, Spacelabs Healthcare Inc. Issaquah, 
Washington). The device cuff was wrapped around the nondominant arm, and the 
patient was asked to keep his or her arm still during the automatic BP measurement. 
Each recording started in the morning, immediately after office BP assessment and 
administration f active treatment, when foreseen. The device was programmed tomea- 
sure BP every 15 minutes during the day (7 AM--11 PM) and every 20 minutes during 
the night (11 PM--7 aM). 
I~ 'CHOCARDIOGRAPHY 
Echocardiography was performed (S.C.) with the patient in the supine left lateral 
decubitus position. Left ventricular internal diameters, left ventricular posterior wall 
thickness, and interventricular septum thickness were measured monodimensionally 
on the longitudinal parasternal view previously identified bidimensionally according to 
the recommendations of the American Society of Echocardiography. 19 Left ventricular 
volumes were calculated using the cube formula, 19 while left ventricular mass was cal- 
culated according to the Penn Convention 2°and indexed to body surface area by the 
formula of Dubois and Dubois5 The presence of left ventricular hypertrophy (LVH) 
was defined as an LVMI >110 g/m 2 in women and >131 g/m 2 in men. 22 
STAT IST ICAL  ANALYS IS  
Treatment effect was assessed by computing office sitting SBP and DBP changes 
(computed as final visit BP - baseline BP), which were considered the primary study 
end points. Secondary study end points were as follows: (1) changes in 24-hour, day- 
time (7 aM--11 PM), and nighttime (11 PM--7 aM) mean SBP and DBP and pulse pres- 
sure (computed as SBP - DBP); (2) 2-hour means of BP before and during treatment; 
(3) changes in SBP and DBP during the last 4 hours of the dosing interval; (4) deter- 
mination of the smoothness index of SBP and DBP after 12 weeks of treatment; and 
(5) changes in office and ambulatory HR. 
Before analyzing the 24-hour BP recordings, artifacts were removed according to 
previously described editing criteria. 23 Recordings were considered valid when <3 non- 
consecutive hours were missing over the 24-hour monitoring period and when _>1 BP 
measurement was available in the remaining hours. 
The smoothness index was computed by dividing the mean of the 24 hourly BP 
changes after treatment by the corresponding SD. 24-26 This index is useful for quan- 
tifying whether treatment smoothly reduces BP throughout the 24-hour monitoring 
period. It has been found to be more reproducible and clinically relevant han other 
indices (eg, the trough-to-peak ratio). 25,26 According to recent publications, the higher 
the smoothness index, the smoother the BP control. 23,27 
Assessment of treatment effect at the final study visit compared with baseline was 
done by analysis of covariance using the baseline value as covariate and treatment as the 
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main effect. Baseline-adjusted mean changes and 95% CIs were computed. This analy- 
sis was applied to office and ambulatory BP, LVMI, PCIP, and NT-proBNP. Analysis of 
variance was used to assess differences in the smoothness index. 
The occurrence of drug-related AEs was monitored uring the study, and the per- 
centage of patients with drug-related AEs in each group was compared using the Fisher 
exact test. 
P < 0.05 was considered statistically significant. Data are shown as mean (SD), unless 
otherwise indicated. Because this was a pilot study, no sample size estimation was done. 
RESULTS 
DEMOGRAPHIC  AND CL IN ICAL  DATA 
Thirty consecutive ligible patients (20 men, 10 women; mean [SD] age, 47 
[12] years) were randomized to either barnidipine 10 mg (n = 15) or amlodipine 5 mg 
(n = 15) once daily. All patients had compliance >95%. No patients in the barnidipine 
group had their drug dose doubled; 6 patients in the amlodipine group had their 
drug dose doubled to 10 mg because their BP was inadequately controlled (office SBP 
>140 mm Hg or office DBP ->90 mm Hg) after 12 weeks of treatment. There were no 
significant differences at baseline between the 2 groups in any demographic or clinical 
characteristics (Table I). Given the strict exclusion criteria used in the study, previous 
and concomitant diseases or treatments were rare (ie, <10% of patients) among study 
patients. All 30 patients completed the 24 weeks of study treatment. 
Nineteen of the 30 patients (63%) (barnidipine group, 9; amlodipine group, 10) had 
valid ambulatory BP recordings. Reasons for exclusion from analysis were unavailability 
Table I. Baseline demographic and clinical characteristics of study patients with essen- 
tial hypertension randomly assigned to I of 2 treatment groups (N = 30).* Data 
are mean (SD) unless otherwise indicated. 
Variable Barnidipine (n = 15) Amlodipine (n = 15) 
Age, y 45 (9) 50 (15) 
Sex, no. (%) 
Male 10 (67) 10 (67) 
Female 5 (33) 5 (33) 
LVMI, g/m 2 125 (31) 115 (25) 
LVH, no. (%) 6 (40) 4 (27) 
PICP, mg/L 60 (28) 47 (13) 
NT-proBNP, pg/mL 64 (44) 41 (26) 
Office SBP, mm Hg 145 (17) 147 (18) 
Office DBP, mm Hg 98 (9) 96 (5) 
Office HR, beats/min 72 (13) 78 (14) 
LVMI = left ventricular mass index; LVH = left ventricular hypertrophy; PICP = procollagen type I 
C-terminal propeptide; NT-proBNP = amino-terminal pro-B-type natriuretic peptide; SBP = systolic blood 
pressure; DBP = diastolic blood pressure; HR = heart rate. 
*No significant between-group differences were found. 
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of 1 or both recordings (n = 7) or <21 hours of valid recordings (n = 4). Demographic 
and clinical characteristics of the patients with valid ambulatory BP recordings were 
similar to those of the total study population (Table II). 
OFF ICE  BLOOD PRESSURE AND HEART RATE MEASUREMENTS 
After 12 weeks of treatment, mean baseline-adjusted office SBP and DBP reductions 
were not significantly different in the barnidipine group (SBP: -15.4 mm Hg [95% 
CI, -21.0 to -9.9]; DBP: -12.1 mm Hg [95% CI, -16.0 to -8.2]) compared with the 
amlodipine group (SBP: -16.3 mm Hg [95% CI, -21.8 to -10.8]; DBP: -10.7 mm Hg 
[95% CI,-15.6 to-6.8]). 
At the end of the 24 weeks of treatment, baseline-adjusted office SBP reductions 
(barnidipine: -10.3 mm Hg [95% CI, -17.3 to -3.4]; amlodipine: -16.6 mm Hg [95% 
Table II. Demographic and clinical characteristics of patients with essential hyperten. 
sion and valid ambulatory blood pressure monitoring during the study (n = 19).* 
Data are mean (SD) unless otherwise indicated. 
Variable Barnidipine (n = 9) Amlodipine (n = 10) 
Age, y 45 (7) 48 (12) 
Sex, no. (%) 
Male 5 (56) 7 (70) 
Female 4 (44) 3 (30) 
LVMI, g/m 2 123 (25) 114 (22) 
LVH, no. (%) 4 (44) 3 (30) 
PICP, mg/L 61 (32) 45 (11) 
NT-proBNP, pg/mL 78 (47) 34 (23) 
Office SBP, mm Hg 144 (18) 145 (17) 
Office DBP, mm Hg 99 (11) 96 (6) 
Office HR, beats/min 66 (9) 77 (15) 
24-Hour SBP, mm Hg 144 (11) 138 (9) 
24-Hour DBP, mm Hg 89 (6) 84 (8) 
24-Hour HR, beats/min 74 (7) 78 (7) 
Daytime SBP, mm Hg 149 (10) 141 (9) 
Daytime DBP, mm Hg 94 (6) 88 (8) 
Daytime HR, beats/min 78 (8) 83 (9) 
Nighttime SBP, mm Hg 130 (14) 130 (9) 
Nighttime DBP, mm Hg 77 (8) 75 (10) 
Nighttime HR, beats/min 65 (7) 68 (5) 
LVMI = left ventricular mass index; LVH = left ventricular hypertrophy; PICP = procollagen type I 
C-terminal propeptide; NT-proBNP = amino-terminal pro-B-type natriuretic peptide; SBP = systolic blood 
pressure; DBP = diastolic blood pressure; HR = heart rate. 
*No significant between-group differences were found. 
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CI, -23.6 to -9.6]) and office DBP reductions (barnidipine: -9.4 mm Hg [95% CI, 
-13.5 to -5.4]; amlodipine: -9.1 mm Hg [95% CI, -13.2 to -5.1]) were not significantly 
different between the 2 treatment groups. 
The mean change in office HR was not significantly different after 12 weeks (barni- 
dipine: -1.7 beats/min [95% CI, -5.9 to 2.6]; amlodipine: -0.9 beats/min [95% CI, 
-3.3 to 5.2]) or 24 weeks (barnidipine: -1.5 beats/min [95% CI, -7.1 to 4.1]; amlodipine: 
-2.0 beats/rain [95% CI, -7.7 to 3.6]) of treatment. 
AMBULATORY BLOOD PRESSURE AND HEART RATE 
In the 19 patients with valid ambulatory BP recordings, 24-hour, daytime, and 
nighttime SBP and DBP values were significantly (all, P < 0.05) reduced by treatment, 
with the exception of nighttime SBP in the amlodipine group (Figure 1). No statisti- 
cally significant between-treatment differences were observed over the 24-hour period 
or during the daytime or the nighttime. 
No significant between-group differences were found in 24-hour pulse pressure 
(barnidipine: -2.9 mm Hg [95% CI, -6.1 to 0.2]; amlodipine: -3.1 mm Hg [95% 
CI, -6.1 to -0.1]), daytime pulse pressure (-2.1 mm Hg [95% CI, -5.2 to 1.0] vs 
-3.4 mm Hg [95% CI, -6.3 to -0.5]), or nighttime pulse pressure (-4.1 mm Hg [95% 
CI, -7.9 to -0.3] vs -3.0 mm Hg [95% CI, -6.6 to 0.6]). 
No significant between-group differences were found in reductions in BP during 
each 2-hour period of the 24-hour monitoring period, including the last 4 hours of 
the recording (barnidipine: SBP, -14.3 mm Hg [95% CI, -18.4 to -10.3] and DBP, 
-7.6 mm Hg [95% CI, -12.7 to -2.4]; amlodipine: -11.6 mm Hg [95% CI, -15.4 to 
-7.8] and -6.0 mm Hg [95% CI, -10.9 to -1.1]) (Figure 2). 
Assessment of homogeneity of BP control using the smoothness index (Figure 3) 
showed no statistically significant difference between the barnidipine and amlodipine 
groups in either SBP or DBP. 
Mean (95% CI) 24-hour (barnidipine: 1 bpm [-4 to 5]; amlodipine: -1 bpm [-6 to 
3]), daytime (barnidipine: 1 bpm [-4 to 5]; amlodipine: -2 bpm [-6 to 3]), and night- 
time HR values (barnidipine: 2 bpm [-3 to 6]; amlodipine: 0 bpm [-4 to 4]) did not 
change significantly in either treatment group. 
MARKERS OF TARGET ORGAN DAMAGE 
Figure 4 shows mean absolute values for LVMI at baseline and after 24 weeks of 
treatment, as well as corresponding baseline-adjusted changes. LVMI was significantly 
reduced (P < 0.05) by treatment with barnidipine but not with amlodipine, with 
no statistically significant difference between the 2 treatment groups. Three of the 
6 patients (50%) with LVH at baseline in the barnidipine group experienced regres- 
sion of this condition with treatment. In the amlodipine group, 1 of 4 patients (25%) 
with LVH experienced regression, but 2 patients who did not have LVH at baseline 
developed the condition by the final visit. 
Serum concentrations of PICP and plasma concentrations of NT-proBNP were 
reduced, though not significantly, by barnidipine (-3.0 mg/L [95% CI, -9.8 to 
3.9] and -7.2 pg/mL [95% CI, -15.2 to 0.9], respectively) but not by amlodipine 
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Figure 3. Mean (SD) smoothness index of systolic (SBP) and diastolic blood pressure 
(DBP) in patients with essential hypertension randomized to treatment with 
barnidipine (n = 9) or amlodipine (n = lO). 
(0.6 mg/L [95% CI, -6.0 to 7.2] and 4.3 pg/mL [95% CI, -3.4 to 12.1]), although 
the difference between the 2 treatment groups was not statistically significant. 
DRUG-RELATED ADVERSE EVENTS 
A total of 11 patients (36.7%) reported drug-related AEs, with a significantly 
greater incidence in the amlodipine group compared with the barnidipine group 
(9 vs 2 patients; P < 0.05). A total of 13 AEs--10 in the amlodipine group and 3 in 
the barnidipine group--were recorded (Table III). No patient was withdrawn from the 
study due to AEs. 
DISCUSSION 
In this pilot study, barnidipine 10 mg was as effective as 5 to 10 mg of amlodipine in 
reducing office BP during 24 weeks of treatment in patients with grade I or II essential 
hypertension who were naive to hypertensive treatment. The incidence of drug-related 
AEs was significantly lower with barnidipine than amlodipine. Barnidipine has previ- 
ously been reported to have a good tolerability profile. 7,28,29 
Both drugs were associated with comparable reductions in BP, not only office BP 
but also 24-hour ambulatory BE Both barnidipine and amlodipine displayed a good 
smoothness index, with no statistically significant difference between treatments. These 
results upport hose of a previous open-label study in 40 Thai patients with essential 
hypertension i which 8 weeks of treatment with higher doses of barnidipine (10- 
15 mg) were associated with consistent 24-hour BP reduction and control, as quantified 
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Figure 4. Mean (SD) left ventricular mass index (LVMI) at baseline and after 24 weeks 
(A) and corresponding baseline-adjusted mean (95% CI) changes (B) in 
patients with essential hypertension randomized to treatment with barnidipine 
or amlodipine. *P < 0.05 versus baseline. 
by the smoothness index. 17 Our study also supports the timings of a review of 12-week 
studies of the antihypertensive effects of barnidipine and amlodipine. 14
In the present study, barnidipine and amlodipine were associated with significantly 
reducing not only 24-hour SBP and DBP but also 24-hour pulse pressure, although the 
reduction in the latter was small. This is an important finding because ven a limited 
reduction in pulse pressure may be clinically and prognostically beneficial for hyperten- 
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Table III. Prevalence of drug-related adverse events (AEs) in patients with essential 
hypertension randomly assigned to I of 2 treatment groups {N = 30). 
AE Barnidipine (n = 15) Amlodipine (n = 15) 
Ankle edema, no. 1 6 
Headache, no. 1 2 
Palpitations, no. 1 2 
Total, no. 3 10 
Total patients with AEs, no. (%) 2 (13) 9 (60)* 
*P  < 0 .05  versus barnidipine.  
sive patients. 3°,31 Also, the fact that HR, a well known cardiovascular risk factor, did 
not increase with barnidipine administration may be regarded as a positive feature of 
this drug, 32 indirectly confirming the previous finding that barnidipine does not cause 
reflex neurohumoral ctivation. 33
LVMI decreased significantly in the barnidipine group. Concentrations of PICP 
and NT-proBNP, which may be increased in hypertensive patients and are considered 
important markers of asymptomatic cardiac damage, also decreased in the barnidipine 
group, though not significantly. 34,35 A possible xplanation for these favorable ffects of 
barnidipine on cardiac organ damage might be due to the drug's lipophilic character, 
which allows it to concentrate in the tissues, 7 and to its antioxidant activity, which has 
potential cardiovascular-protective effects. 36,37 
Finally, our findings deserve some notes of caution. This was a single-center, open- 
label, pilot study with a limited sample size. Larger controlled, blinded studies are 
needed to demonstrate whether the antihypertensive effects of barnidipine are similar to 
those of amlodipine. Another limitation of our study was the analysis of ambulatory BP 
recordings, which was limited for technical reasons to 63% of the study patients; this 
occurred because many recordings were missing or qualitatively inadequate. Therefore, 
although it is known that when drug efficacy is tested using 24-hour BP monitoring 
fewer patients are needed ue to the lack of a placebo effect 38,39 and to high reproduc- 
ibility, 4° we cannot definitely conclude that barnidipine was similar to amlodipine in 
controlling 24-hour BP. However, this is the first study comparing barnidipine and 
amlodipine in newly diagnosed, treatment-naive hypertensive patients. 
Another limitation of our study is that, in spite of similar office BP at baseline, 
patients treated with amlodipine had values of LVMI, PICP, NT-proBNP, and daytime 
BP numerically lower than those recorded in patients treated with amlodipine. This 
finding may be compatible with a larger prevalence of patients with a "white-coat 
effect" in the group of patients treated with amlodipine, this condition being also 
characterized by less pronounced signs of cardiac damage, as in our patients. Although 
this nonhomogeneity might have led to a better esponse in patients treated with amlo- 
dipine, no significant differences between treatments were observed after correction of 
on-treatment changes by baseline values. 
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CONCLUSIONS 
In this randomized, open-label, pilot study in a small sample of treatment-naive hyper- 
tensive patients, the antihypertensive effect of barnidipine 10 mg once daily was not 
significantly different from that of amlodipine 5 to 10 mg once daily. The effects on 
LVMI and on concentrations of PICP and NT-proBNP, markers of cardiac damage, were 
not significantly different between the 2 drugs. 
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